Tiziana Life Sciences Ltd (TLSA) Form 6-K — Nov 2, 2026
Tiziana Life Sciences announced positive topline results from its Phase 2a INFORM-MS trial of intranasal foralumab in non-active secondary progressive MS. The trial met both dual primary endpoints: a statistically significant reduction in microglial activation on TSPO PET imaging in the 50 ug arm (p=0.0168) versus placebo, and safety/tolerability. Foralumab-treated patients showed clinically significant fatigue improvement on the Modified Fatigue Impact Scale after 12 weeks: -6.17 points in the 50 ug arm (p=0.035) and -7.18 in the 100 ug arm (p=0.040), versus -3.12 on placebo. All 48 participants completed treatment with no deaths or drug-related serious adverse events.
Key figures
- Placebo n
- 18
- Dose 50ug n
- 19
- Dose 100ug n
- 11
- Clinical sites
- 8
- Mfis change 50ug
- -6.17 (p=0.035)
- Trial enrollment
- 48
- Mfis change 100ug
- -7.18 (p=0.040)
- Mfis change placebo
- -3.12
- Primary endpoint p value
- 0.0168
- Treatment duration weeks
- 12
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.